ALIVUSAlivus Life Sciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
₹1,132.30
▼ 0.09%Strong
Price & Volume
Loading chart…
Key Ratios
Market Cap (₹ cr)13,910.10
P/E24.71
P/B4.18
PEG1.70
ROE %18.36
ROCE %21.30
Debt / Equity0.02
EPS45.87
Revenue Growth %6.10
Profit Growth %14.50
Dividend Yield %0.44
Promoter Holding %76.10
FII Holding %8.79
DII Holding %—
Beta0.05
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
| Pullback to 21-EMA | LONG | 80% | ₹1,132.30 | ₹1,096.67 | ₹1,215.00 | 2.32 |
BUYConviction 83%
Why buy
- • ROE: 18.4%
- • ROCE: 21.3%
- • Debt/Equity: 0.02
- • RSI: 53
- • Price vs EMA21: above
- • Price vs SMA50: above
- • Pullback to 21-EMA signal (setup quality 80%)
Bull case
- • ROE: 18.4%
- • ROCE: 21.3%
- • Debt/Equity: 0.02
- • RSI: 53
Bear case
- • Revenue growth: 6.1% YoY
- • Dividend yield: 0.44%
- • MACD: bearish
- • Volume: 0.3x 20-day average
Key risks
- • Revenue growth: 6.1% YoY
- • Dividend yield: 0.44%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Entry (CMP)
₹1,132.30
Stop Loss
₹1,074.15
risk 5.1%
Target 1 (1.5R)
₹1,219.53
+7.7%
Target 2 (3R)
₹1,306.75
+15.4%
Support (20d)
₹1,085.00
Resistance (52w)
₹1,193.90
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹58.15/share
ATR (volatility)
₹35.63
avg daily range
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹35.63). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.
Score Breakdown
Fundamental
73
Technical
65
Momentum
77
Risk (safety)
72